AEON Biopharma, Inc. (AEON)
0.1616
0.00 (0.00%)
USD |
NYAM |
Nov 06, 10:20
AEON Biopharma Enterprise Value : 3.503M for Nov. 5, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 05, 2026 | 3.503M |
| November 04, 2026 | 4.832M |
| November 03, 2026 | 4.926M |
| November 02, 2026 | 6.526M |
| October 30, 2026 | 6.552M |
| October 29, 2026 | 7.078M |
| October 28, 2026 | 6.289M |
| October 27, 2026 | 5.876M |
| October 26, 2026 | 5.658M |
| October 23, 2026 | 5.655M |
| October 22, 2026 | 5.492M |
| October 21, 2026 | 5.663M |
| October 20, 2026 | 5.434M |
| October 19, 2026 | 5.421M |
| October 16, 2026 | 5.447M |
| October 15, 2026 | 5.737M |
| October 14, 2026 | 5.366M |
| October 13, 2026 | 5.387M |
| October 12, 2026 | 5.805M |
| October 09, 2026 | 6.605M |
| October 08, 2026 | 7.499M |
| October 07, 2026 | 7.532M |
| October 06, 2026 | 6.965M |
| October 05, 2026 | 6.447M |
| October 02, 2026 | 6.684M |
| Date | Value |
|---|---|
| October 01, 2026 | 6.973M |
| September 30, 2026 | 7.236M |
| September 29, 2026 | 6.158M |
| September 28, 2026 | 6.226M |
| September 25, 2026 | 6.279M |
| September 24, 2026 | 6.189M |
| September 23, 2026 | 6.286M |
| September 22, 2026 | 6.236M |
| September 21, 2026 | 6.026M |
| September 18, 2026 | 5.724M |
| September 17, 2026 | 5.824M |
| September 16, 2026 | 6.105M |
| September 15, 2026 | 6.331M |
| September 14, 2026 | 6.873M |
| September 11, 2026 | 7.944M |
| September 10, 2026 | 6.973M |
| September 09, 2026 | 5.421M |
| September 08, 2026 | 5.526M |
| September 04, 2026 | 5.679M |
| September 03, 2026 | 6.044M |
| September 02, 2026 | 6.473M |
| September 01, 2026 | 6.621M |
| August 31, 2026 | 7.128M |
| August 28, 2026 | 7.610M |
| August 27, 2026 | 7.076M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ACADIA Pharmaceuticals, Inc. | 2.737B |
| Alnylam Pharmaceuticals, Inc. | 20.38B |
| Anika Therapeutics, Inc. | 245.53M |
| Savara, Inc. | 757.02M |
| Vericel Corp. | 2.582B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -1.155M |
| Total Expenses (Quarterly) | 1.155M |
| EPS Diluted (Quarterly) | -0.0229 |
| Earnings Yield | -2.33K% |
| Normalized Earnings Yield | -1610.89 |